• 1. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 2. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 3. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480

Introduction to 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one (CAS No. 898764-74-4)

3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and chemical research due to its unique structural properties and potential applications. This compound, identified by the Chemical Abstracts Service Number (CAS No.) 898764-74-4, belongs to a class of molecules that exhibit promising characteristics for use in various biochemical and medicinal contexts. The presence of both bulky alkyl groups and a trifluoromethyl substituent on the aromatic ring imparts distinct electronic and steric effects, making it a valuable candidate for further investigation.

The molecular structure of 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one can be broken down into several key components that contribute to its reactivity and functionality. The dimethyl groups at the 3-position of the butanone backbone enhance the stability of the molecule while also influencing its solubility and metabolic pathways. The aromatic ring substituted with a trifluoromethyl group is particularly noteworthy, as trifluoromethylation is a common strategy in drug design to improve metabolic stability and binding affinity to biological targets.

In recent years, there has been a surge in research focused on the development of novel compounds with fluorine-containing moieties due to their ability to modulate pharmacokinetic properties. The trifluoromethyl group, in particular, has been extensively studied for its role in enhancing lipophilicity, reducing metabolic clearance, and improving binding interactions with enzymes and receptors. This makes 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one a compelling candidate for further exploration in medicinal chemistry.

One of the most intriguing aspects of this compound is its potential application in the synthesis of bioactive molecules. The combination of a ketone functional group and an aromatic ring with a trifluoromethyl substituent provides multiple sites for chemical modification, allowing for the creation of derivatives with tailored biological activities. For instance, researchers have explored its use as a precursor in the synthesis of ligands for G-protein coupled receptors (GPCRs), which are critical targets in drug development due to their involvement in numerous physiological processes.

Recent studies have also highlighted the compound's relevance in the context of inflammation and pain management. The structural features of 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one suggest that it may interact with inflammatory pathways by modulating the activity of key enzymes such as cyclooxygenases (COX) or lipoxygenases (LOX). These enzymes are pivotal in the production of prostaglandins and other mediators that contribute to inflammation and pain responses. By targeting these pathways, 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one could potentially serve as a lead compound for developing novel anti-inflammatory agents.

The pharmacokinetic profile of 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one is another area of interest. The presence of the trifluoromethyl group not only enhances lipophilicity but also influences metabolic stability by resisting oxidative degradation. This characteristic is particularly advantageous in drug development, where prolonged half-life can lead to more effective therapeutic outcomes. Additionally, the bulky alkyl groups may contribute to reduced permeability through biological membranes, potentially leading to improved oral bioavailability.

In vitro studies have begun to uncover the potential biological activities of this compound. Initial experiments suggest that it may exhibit inhibitory effects on certain enzymes involved in cancer metabolism. The ability of fluorinated compounds to interfere with key metabolic pathways has been well-documented, making them attractive candidates for oncological research. Further investigation into the mechanisms by which 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one affects cellular processes could lead to new insights into its therapeutic potential.

The synthesis of 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one presents an interesting challenge due to its complex structure. Traditional synthetic routes often involve multi-step processes that require careful optimization to ensure high yield and purity. Advances in synthetic methodologies, such as transition metal-catalyzed reactions and flow chemistry techniques, have made it possible to streamline these processes and improve efficiency. These advancements not only facilitate the production of this compound but also open avenues for synthesizing related derivatives with enhanced properties.

The role of computational chemistry in studying 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one cannot be overstated. Molecular modeling techniques allow researchers to predict binding affinities, optimize molecular structures, and simulate interactions with biological targets before conducting experimental validation. This approach has significantly reduced the time and resources required for drug discovery programs. By integrating computational methods with experimental data, scientists can accelerate the development process and increase the likelihood of success in identifying novel bioactive compounds.

Future directions in research on 3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]butan-1-one include exploring its potential as an intermediate in larger synthetic schemes and investigating its interactions with complex biological systems. The compound's unique structural features make it a versatile building block for creating new molecules with tailored properties. Additionally, understanding its behavior within living systems will provide critical insights into its pharmacological profile and potential therapeutic applications.

In conclusion, 898764-74 4 CAS No.-indicated 898764 -74 -4 898764 -74 -4 product name 898764 -74 -4 offers significant promise as a pharmaceutical intermediate due to its structural complexity and functionalizable nature . With ongoing research focusing on its biological activities pharmacokinetic profile , synthesis , and computational modeling , this compound continues to be a subject of intense investigation . Its potential applications span various therapeutic areas , making it a valuable asset in modern drug discovery efforts . p > article > response >

• 898764-76-6(3,3-dimethyl-1-[4-(trifluoromethyl)phenyl]butan-1-one)
• 62587-07-9(cyclopropyl-[4-(trifluoromethyl)phenyl]methanone)
• 898765-80-5( )
• 38675-82-0(cyclopropyl-[3-(trifluoromethyl)phenyl]methanone)
• 898765-82-7( )
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)